As of 2025-10-24, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.8x - 13.6x | 12.5x |
| Forward P/E multiples | 11.4x - 13.3x | 11.6x |
| Fair Price | (42.11) - (50.26) | (45.12) |
| Upside | -123.6% - -128.1% | -125.2% |
| Date | EV/EBITDA |